MX360498B - Compuesto novedoso de pirimidina fusionada o sal del mismo. - Google Patents

Compuesto novedoso de pirimidina fusionada o sal del mismo.

Info

Publication number
MX360498B
MX360498B MX2016001845A MX2016001845A MX360498B MX 360498 B MX360498 B MX 360498B MX 2016001845 A MX2016001845 A MX 2016001845A MX 2016001845 A MX2016001845 A MX 2016001845A MX 360498 B MX360498 B MX 360498B
Authority
MX
Mexico
Prior art keywords
salt
pyrimidine compound
fused pyrimidine
present
novel fused
Prior art date
Application number
MX2016001845A
Other languages
English (en)
Other versions
MX2016001845A (es
Inventor
Satoru Iguchi
Takeshi Sagara
Hosoi Fumihito
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MX2016001845A publication Critical patent/MX2016001845A/es
Publication of MX360498B publication Critical patent/MX360498B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se proporciona un compuesto novedoso que tiene acción inhibidora de BTK y un efecto de supresión de la proliferación celular; también se proporciona un medicamento útil para la prevención y/o tratamiento de una enfermedad relacionada con BTK, particularmente cáncer, con base en la acción inhibidora de BTK; se describe un compuesto representado por la fórmula (I) [en donde R1 a R3, W, A, Y y Z respectivamente tienen los significados como se definió en la especificación], o una sal del mismo. (ver Fórmula).
MX2016001845A 2013-08-12 2014-08-11 Compuesto novedoso de pirimidina fusionada o sal del mismo. MX360498B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013167600 2013-08-12
PCT/JP2014/071158 WO2015022926A1 (ja) 2013-08-12 2014-08-11 新規な縮合ピリミジン化合物又はその塩

Publications (2)

Publication Number Publication Date
MX2016001845A MX2016001845A (es) 2016-05-16
MX360498B true MX360498B (es) 2018-11-05

Family

ID=52468312

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001845A MX360498B (es) 2013-08-12 2014-08-11 Compuesto novedoso de pirimidina fusionada o sal del mismo.

Country Status (23)

Country Link
US (1) US9580432B2 (es)
EP (1) EP2947086B1 (es)
JP (1) JP6035423B2 (es)
KR (1) KR101828187B1 (es)
CN (1) CN105452257B (es)
AU (1) AU2014307437B2 (es)
BR (1) BR112016002069B1 (es)
CA (1) CA2921208C (es)
DK (1) DK2947086T3 (es)
ES (1) ES2661733T3 (es)
HK (1) HK1217703A1 (es)
HU (1) HUE036834T2 (es)
MX (1) MX360498B (es)
MY (1) MY171831A (es)
NO (1) NO2947086T3 (es)
PH (1) PH12015502737A1 (es)
PL (1) PL2947086T3 (es)
PT (1) PT2947086T (es)
RU (1) RU2666349C2 (es)
SG (1) SG11201600048VA (es)
TR (1) TR201802875T4 (es)
TW (1) TWI585089B (es)
WO (1) WO2015022926A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX369863B (es) 2013-08-23 2019-11-25 Neupharma Inc Ciertas entidades quimicas, composiciones y metodos.
PT3115365T (pt) * 2015-01-30 2018-05-07 Taiho Pharmaceutical Co Ltd Novo sal de composto pirimidina fundido e cristal do mesmo
JP6093485B2 (ja) * 2015-01-30 2017-03-08 大鵬薬品工業株式会社 免疫疾患の予防及び/又は治療剤
PL3345907T3 (pl) * 2015-09-01 2020-09-07 Taiho Pharmaceutical Co., Ltd. Związki pirazolo[3,4-d]pirymidynowe lub ich sole
MA41559A (fr) * 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
TWI642671B (zh) * 2015-10-28 2018-12-01 台灣神隆股份有限公司 依魯替尼之製備方法及其中間體
AU2017222908B2 (en) 2016-02-23 2021-02-04 Taiho Pharmaceutical Co., Ltd. Novel condensed pyrimidine compound or salt thereof
CN109843858B (zh) * 2016-08-15 2023-05-05 润新生物公司 某些化学实体、组合物及方法
EP3590516A4 (en) * 2017-02-28 2020-12-09 Taiho Pharmaceutical Co., Ltd. ANTITUMOR AMPLIFIER WITH PYRAZOLO [3,4-D] PYRIMIDINE COMPOUND
SG11202107528PA (en) * 2019-01-11 2021-08-30 Taiho Pharmaceutical Co Ltd Pyrimidine compound or salt thereof
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
US20230064254A1 (en) * 2019-12-19 2023-03-02 Taiho Pharmaceutical Co., Ltd. Therapeutic agent containing fused pyrimidine compound as active ingredient
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR20230031926A (ko) 2020-07-15 2023-03-07 다이호야쿠힌고교 가부시키가이샤 종양의 치료에 사용되는 피리미딘 화합물을 포함하는 조합
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
CN114736207B (zh) * 2022-04-28 2023-03-31 武汉九州钰民医药科技有限公司 一种小分子her2抑制剂的制备工艺

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06004680A (es) 2003-10-27 2007-04-17 Genelabs Tech Inc Compuestos de nucleosido para el tratamiento de infecciones virales.
US20070135387A1 (en) 2005-12-08 2007-06-14 Michaelides Michael R Inhibitors of protein kinases
CN101460161A (zh) 2006-03-29 2009-06-17 弗尔德里克斯制药股份有限公司 α-突触核蛋白毒性的抑制
ES2403546T3 (es) 2006-11-03 2013-05-20 Pharmacyclics, Inc. Sonda de actividad de la tirosina-cinasa de Bruton y procedimiento de utilización
SG10201508035TA (en) 2007-03-28 2015-10-29 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
WO2009057733A1 (ja) * 2007-10-31 2009-05-07 Santen Pharmaceutical Co., Ltd. 血管新生阻害活性を有する新規インドール誘導体
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
EP3549934A1 (en) 2008-06-27 2019-10-09 Celgene CAR LLC Heteroaryl compounds and uses thereof
JP2014520863A (ja) * 2011-07-13 2014-08-25 ファーマサイクリックス,インク. Bruton型チロシンキナーゼの阻害剤
CN105771039B (zh) * 2011-07-15 2020-01-10 赛诺菲-安万特德国有限公司 药物输送装置
AU2013210403B2 (en) * 2012-01-19 2016-01-14 Taiho Pharmaceutical Co., Ltd. 3,5-disubstituted alkynylbenzene compound and salt thereof
CN104250250A (zh) * 2013-06-25 2014-12-31 苏州科捷生物医药有限公司 4-芳香胺基嘧啶类化合物及其抗肿瘤用途

Also Published As

Publication number Publication date
EP2947086A1 (en) 2015-11-25
ES2661733T3 (es) 2018-04-03
US20160115168A1 (en) 2016-04-28
AU2014307437A1 (en) 2016-01-21
AU2014307437B2 (en) 2016-12-15
HUE036834T2 (hu) 2018-08-28
KR20160038891A (ko) 2016-04-07
EP2947086A4 (en) 2016-06-22
PH12015502737B1 (en) 2016-03-07
RU2015156524A (ru) 2017-09-14
CA2921208C (en) 2018-02-20
HK1217703A1 (zh) 2017-01-20
JP6035423B2 (ja) 2016-11-30
TW201536786A (zh) 2015-10-01
TR201802875T4 (tr) 2018-03-21
BR112016002069B1 (pt) 2020-08-18
MX2016001845A (es) 2016-05-16
MY171831A (en) 2019-11-01
BR112016002069A2 (pt) 2017-08-01
TWI585089B (zh) 2017-06-01
SG11201600048VA (en) 2016-03-30
JPWO2015022926A1 (ja) 2017-03-02
CN105452257B (zh) 2017-09-05
US9580432B2 (en) 2017-02-28
KR101828187B1 (ko) 2018-02-09
PL2947086T3 (pl) 2018-06-29
EP2947086B1 (en) 2018-01-03
RU2666349C2 (ru) 2018-09-07
NO2947086T3 (es) 2018-06-02
CN105452257A (zh) 2016-03-30
DK2947086T3 (en) 2018-03-19
CA2921208A1 (en) 2015-02-19
PT2947086T (pt) 2018-03-09
WO2015022926A1 (ja) 2015-02-19
PH12015502737A1 (en) 2016-03-07

Similar Documents

Publication Publication Date Title
PH12015502737A1 (en) Novel fused pyrimidine compound or salt thereof
SG11201806930PA (en) Novel condensed pyrimidine compound or salt thereof
MX2022002579A (es) Compuestos de aminotiazol como inhibidores de c- kit.
PH12017502363A1 (en) Brk inhibitory compound
MD20160106A2 (ro) Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4
MX364486B (es) Derivados de piridazinona-amidas.
MD4666B1 (ro) Inhibitori ai Syk
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
PH12014502396B1 (en) Nitrogenated heterocyclic compound
PH12016500225B1 (en) Novel quinoline-substituted compound
MX2014005928A (es) Inhibidores ciclicos de glutaminasa.
BR112015000399A2 (pt) derivados de pirazolil pirimidina
MX2014002442A (es) Inhibidores de pirrolopirazina cinasa.
MX352928B (es) Compuestos de piridazina-amida.
UA113470C2 (xx) Піримідинові та піридинові сполуки та їх застосування
MX367897B (es) Derivados de piridazinona macrociclicos.
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
PH12016502130B1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
EA201790207A1 (ru) Новые замещенные пиримидиновые соединения
MX366839B (es) Pirimidinas novedosas 2,5-sustituidas como inhibidores de pde4.
MX349548B (es) Compuestos de tienopirimidina.
MX2015013936A (es) Compuestos de pirimidina condensada sustituida.
MX2017000522A (es) Pirimidinas novedosas 2,5-sustituidas como inhibidores de pde.
PH12017500492A1 (en) Crystalline bace inhibitors
MX2015009678A (es) Compuestos de pirimidina condensada sustituida con amino en la posicion 4 como inhibidores de fosfodiesterasa 4 (pde4).

Legal Events

Date Code Title Description
FG Grant or registration